Private Advisor Group, LLC Genmab A/S Transaction History

Private Advisor Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	BUY	$26.83 - $38.57 $10,812 - $15,543	403 Added 2.0%	20,522 $666,000
Q1 2022 May 12, 2022	BUY	$30.95 - $39.68 $120,426 - $154,394	3,891 Added 23.98%	20,119 $728,000
Q4 2021 Feb 10, 2022	SELL	$35.87 - $47.12 $462,974 - $608,177	-12,907 Reduced 44.3%	16,228 $642,000
Q3 2021 Oct 14, 2021	BUY	$41.55 - $48.72 $622,834 - $730,312	14,990 Added 105.97%	29,135 $1.27 Million
Q2 2021 Aug 12, 2021	BUY	$32.88 - $44.57 $39,686 - $53,795	1,207 Added 9.33%	14,145 $577,000
Q1 2021 Apr 22, 2021	SELL	$30.92 - $44.4 $57,573 - $82,672	-1,862 Reduced 12.58%	12,938 $425,000
Q4 2020 Apr 01, 2021	BUY	$33.66 - $40.76 $115,487 - $139,847	3,431 Added 30.18%	14,800 $602,000
Q3 2020 Nov 02, 2020	BUY	$33.07 - $38.68 $18,056 - $21,119	546 Added 5.04%	11,369 $399,000
Q2 2020 Aug 17, 2020	BUY	$20.05 - $33.89 $217,001 - $366,791	10,823 New	10,823 $367,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.